SARS-COV-2 test kit AESKULISA®

for serologyIgAIgG

AESKULISA® for qualitative and quantitative demonstration of IgA, IgG, or IgM antibodies directed against a range of different pathogens supporting a reliable diagnosis of infectious diseases. Immunoassays are important in routine laboratory services for identification of antibodies in serum or plasma specimens. AESKULISA® (AESKU Enzyme-Linked Immunosorbent Assay) is a test format particularly suited for the qualitative and quantitative determination of specific IgA, IgG, or IgM antibodies directed against a range of different pathogens. The following AESKULISA® tests are available order to support the diagnosis of infectious diseases. All assays are calibrated according to our clinically well-characterized, internal Quality Control panels and to all of the latest international standards. It ensures the reliability and reproducibility of our AESKULISA® kits. Intended Use: The AESKULISA® SARS-CoV-2 IgA, IgG and IgM tests are qualitative and quantitative immuno-assays for the demonstration of human IgA, IgG or IgM antibodies in serum or plasma directed against the nucleocapsid protein of SARS-CoV-2. The AESKULISA® SARS-CoV-2 NP IgM and IgA tests assist in the detection of acute infections. The AESKULISA® SARS-CoV-2 NP IgG test serves for confirmation of a contact with the pathogen and supports in immune status determination. Recombinant Antigens: Recombinant Nucleocapsid Protein from SARS-CoV-2 Native Antigens: n.a. Cut Off: - 8-12 U/ml Range: - 3 - 100 U/ml Standard: - -